The Royal Lancaster Infirmary is a hospital in the city of Lancaster, England. It lies to the south of the city centre, between the A6 road and the Lancaster Canal. It is managed by the University Hospitals of Morecambe Bay NHS Foundation Trust.

There are 387 beds in Royal Lancaster Infirmary.

During the past decade, Royal Lancaster Infirmary conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 5 clinical trials were completed, i.e. on average, 38.5% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Royal Lancaster Infirmary" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Gilead Sciences" with 2 trials sponsored, "Institute of Cancer Research, United Kingdom" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "Lancaster University" with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Royal Lancaster Infirmary" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Cancer Research UK" with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator, "European Society of Intensive Care Medicine" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Royal Lancaster Infirmary" are "Breast Cancer" (3 trials), "Colorectal Cancer" (3 trials), "Ovarian Cancer" (3 trials), "Thromboembolism" (3 trials) and "COVID-19" (2 trials). Many other conditions were trialed in "Royal Lancaster Infirmary" in a lesser frequency.

Most popular intervention types in "Royal Lancaster Infirmary" are "Drug" (21 trials), "Procedure" (5 trials), "Other" (4 trials), "Biological" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "adjuvant therapy" (3 trials), "capecitabine" (3 trials), "Atezolizumab" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Royal Lancaster Infirmary" are 20 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Royal Lancaster Infirmary". undefined are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Royal Lancaster Infirmary, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Royal Lancaster Infirmary, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".